Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy

Cancer

Volumn 98, Issue 3, 2003, Pages 504-507

  Esmaeli, Bita ^a   Hidaji, Lillie ^a   Adinin, Rosnie B ^a   Faustina, Misha ^a   Coats, Carol ^a   Arbuckle, Rebecca ^a   Rivera, Edgardo ^a   Valero, Vicente ^a   Tu, Shi Ming ^a   Ahmadi, M Amir ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Canalicular stenosis; Docetaxel; Epiphora; Nasolacrimal duct blockage

Indexed keywords

DOCETAXEL; DOXORUBICIN; ESTRAMUSTINE; IMATINIB; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; DACRYOCYSTORHINOSTOMY; EPIPHORA; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; LACRIMAL DUCT OCCLUSION; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; SQUAMOUS CELL CARCINOMA; TUBE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DACRYOCYSTORHINOSTOMY; DRAINAGE; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INTUBATION; LACRIMAL DUCT OBSTRUCTION; LUNG NEOPLASMS; MALE; MIDDLE AGED; NASOLACRIMAL DUCT; OVARIAN NEOPLASMS; PACLITAXEL; PROSTATIC NEOPLASMS; TAXOIDS; TEXAS;

EID: 0037623700     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11527     Document Type: Article

References (12)

1. Esmaeli B, Valero V, Ahmadi MA, Booser D. Canalicular stenosis secondary to docetaxel (Taxotere): a newly recognized side effect. Ophthalmology. 2001;108:994-995.
2. Esmaeli B, Hortobagyi G, Esteva F, et al. Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect. Ann Oncol. 2002;13:218-221.
3. Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving weekly docetaxel. Arch Ophthalmol. 2001;119:1802-1804.
4. Esmaeli B, Hortobagyi GN, Esteva FJ, et al. Canalicular stenosis secondary to weekly versus every-three-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology. 2002;109:1188-1191.
5. Esmaeli B, Ahmadi MA, Rivera E, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol. 2002;120:1180-1182.
6. Costa SD, von Minckwitz G, Raab G, et al. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer. Semin Oncol. 1999;26:24-31.
7. Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000;18:1212-1219.
8. Esteva FJ, Valero V, Booser D, et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2 overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:1800-1808.
9. Aihara T, Kim Y, Takatsuku Y. Phase II study of weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2002;13:286-292.
10. Hainsworth JD, Burris HA, Yardley DA, et al. Weekly docetaxel in the treatment of elderly patients with advanced breast cancer. J Clin Oncol. 2001;19:3500-3505.
11. Correia O, Azevedo C, Pinto Ferreira E, et al. Nail changes secondary to docetaxel (Taxotere). Dermatology. 1999;198:288-290.
12. Bakri SJ, Carney AS, Robinson K, et al. Quality of life outcomes following dacryocystorhinostomy: external and endonasal laser techniques compared. Orbit. 1999;18:83-88.